MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Core Insights - MiNK Therapeutics is presenting ongoing Phase 2 study results of agenT-797 for refractory gastric cancer at the ASCO GI Symposium in January 2025 [1][2] Group 1: Presentation Details - The abstract title for the presentation is "A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma" [2] - The presentation will take place on January 23, 2025, from 11:30 AM to 1:00 PM [2] - Complete abstracts will be released on January 21, 2025, at 5:00 PM ET [2] Group 2: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [3] - The company is advancing a pipeline of both native and next-generation engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [3] - MiNK Therapeutics is headquartered in New York, NY, and provides investor information on its website and social media [3]